Edition:
India

Almirall SA (ALM.MC)

ALM.MC on Madrid SE C.A.T.S.

9.66EUR
23 Oct 2020
Change (% chg)

€0.04 (+0.42%)
Prev Close
€9.62
Open
€9.61
Day's High
€9.68
Day's Low
€9.59
Volume
294,337
Avg. Vol
501,517
52-wk High
€18.50
52-wk Low
€8.80

Select another date:

Mon, Jul 27 2020

UPDATE 1-Spain's Almirall said coronavirus to hit 2020 sales, earnings

BARCELONA, July 27 Spanish pharmaceutical firm Almirall lowered its 2020 outlook on Monday, forecasting a decrease in net sales and core earnings after the coronavirus pandemic hit its dermatology business, bringing net profit down 31.5% in the first semester.

BRIEF-Almirall Divests Ansiolin To Neuraxpharm In Italy

* SAID ON THURSDAY IT DIVESTED ANSIOLIN (DIAZEPAM) TO NEURAXPHARM IN ITALY

BRIEF-Almirall Announces FDA Approval Of Updated Label For Seysara Tablets

* ALMIRALL ANNOUNCES FDA APPROVAL OF UPDATED LABEL FOR SEYSARA® (SARECYCLINE) TABLETS

UPDATE 2-Spain's Almirall sees easing profits as virus impact evolves

* CFO says will be cautious looking for market opportunities (Adds CFO interview quotes, share details)

Almirall's profit may fall in Q2, outlook will depend on pandemic - CFO

BARCELONA, May 11 Spain's Almirall does not expect to swing to a loss in the second quarter but its profit may decrease as it deals with the coronavirus pandemic's impact, its Chief Financial Officer Mike McClellan told Reuters on Monday .

Spain's Almirall posts Q1 net profit hike, ties outlook to coronavirus impact

BARCELONA, May 11 Spain's Almirall reported on Monday its first quarter net profit rose 63% and kept its 2020 outlook though it added the novel coronavirus pandemic evolution in the second quarter may prompt an outlook revision.

BRIEF-Almirall Q1 Net Profit Up At 48.6 Mln Euros YoY, Maintains Guidance

* Q1 REVENUE 247.3 MILLION EUROS VERSUS 232.2 MILLION EUROS YEAR AGO

Select another date: